Samsung Medical Center Celebrates 20,000 Robotic Surgeries

Samsung Medical Center recently commemorated a significant achievement, having conducted 20,000 robotic surgeries.

Since the launch of the Samsung Comprehensive Cancer Center(SCCC) in 2008, the institution has been at the forefront of robotic surgery, experiencing rapid growth each year. In 2023 alone, the center performed over 3,400 robotic surgeries, placing it 9th globally. Notably, Samsung Medical Center ranks 2nd worldwide for prostate cancer surgeries (prostatectomy), 2nd for gastrectomy (stomach cancer), and 3rd for mastectomy (breast cancer). 

Intuitive Surgical, Inc., the manufacturer of the da Vinci Surgical System, has named Samsung Medical Center as the “Epicenter” for genitourinary cancer in Korea. This distinction makes Samsung Medical Center the first hospital in Korea to receive such recognition for urologic cancer. The hospital currently utilizes eight da Vinci robots and is set to increase this number to nine with the addition of a new single-port robot later this year. This advanced system will offer enhanced 3D HD camera and improved access to confined and deep tissue areas, facilitating more precise and detailed surgical procedures. 

“Since the establishment of SCCC, our robotic surgery has seen remarkable growth, culminating in our 20,000th surgery,” said Jeon Seong-soo, Director of the Robotic Surgery Center and Professor of Urology. “As we strive to become a leading fourth-generation hospital, we are committed to further advancing robotic surgery technologies to improve patient care.” For further details, please contact the Samsung Medical Center public relations department.